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Introduction
L
iver  biopsy  (LB)  plays  a  key  role  in  the 
diagnosis and monitoring of diffuse chronic 
hepatitis, especially for its staging (1-4). The prognosis 
and management of a patient with chronic hepatitis 
C virus (HCV) infection depend very much on the 
severity of liver fibrosis (4), which can be assessed by 
several methods: LB, considered the “gold standard”; 
serological  markers  (FibroTest  being  the  most 
frequently used); and elastographic methods: non-
invasive techniques based on liver tissue elasticity. 
Although considered the “gold standard”, LB is 
not a perfect method; there are a number of problems 
related to the diagnosis of cirrhosis (5): the inequality 
of fibrosis in the two liver lobes in paired LB (6); also 
inter-and intra-observer variability in the evaluation of 
specimens obtained by LB (5, 7). In addition, LB is an 
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Background and Aims: To compare several non-invasive methods of fibrosis assessment in chronic hepatitis C virus (HCV) 
infection (platelet count, the APRI score, the Forns score, the Lok score, FIB-4, Transient Elastography [TE]), versus 
percutaneous liver biopsy (LB).
Methods: Our study included 150 patients with chronic HCV infection in which LB, liver stiffness measurement (LSM) by 
means of TE and biological tests needed for calculating the scores (according to the classic formulas) were performed in 
the same session. 
Results: The best test for predicting significant fibrosis (F ≥ 2 Metavir) was LSM with AUROC-0.773, followed by APRI 
(AUROC-0.763), Forns (AUROC-0.744), platelet count (AUROC-0.732), Lok (AUROC-0.701) and FIB-4 (AUROC-0.669), 
but the differences were not statistically significant (P > 0.05). For excluding cirrhosis, all the tests had excellent NPV 
(>97%). The best test for predicting cirrhosis was LSM (AUROC-0.979), significantly better than platelet count (AUROC-
0.899, P = 0.022) and than FIB-4 (AUROC-0.839, P = 0.042), otherwise the differences were not statistically significant 
(P > 0.05). All of the non-invasive tests were statistically significantly correlated (P < 0.0001) to the severity of fibrosis: 
APRI r=0.570; Forns r=0.540; Lok r=0.4843; FIB-4 r=0.4171; platelet count r=-0.4842.
Conclusions: LSM by means of TE seems to be more sensitive than APRI, Forns, Lok and FIB-4 scores and than platelet 
count for the prediction of significant fibrosis, but the differences are not statistically significant. The APRI score and 
Forns scores correctly identified most (71%) of the patients having, or not having, significant fibrosis. LSM was the best 
method for predicting cirrhosis, but all the evaluated tests had excellent predictive value (AUROCs 0.839-0.979).
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invasive maneuver, (with a risk of complications, even 
if it is low) causing discomfort for the patients (8-11).
 For  these  reasons,  non-invasive  methods  of 
assessing the severity of fibrosis which may someday 
completely replace LB, are constantly being searched 
for. Among the non-invasive tests, the best results were 
obtained with liver stiffness measurement (LSM) by 
means of transient elastography (TE) (FibroScan®), 
and  with  FibroTest-ActiTest®  (Biopredictive, 
Labcorp) (12) and Fibrospect II® (Prometheus) (13). 
All these non-invasive methods are expensive and/
or require equipment that is not widely available; 
therefore simpler, cheaper methods for the prediction 
of hepatic fibrosis were sought for. 
The  aim  of  this  study  was  to  evaluate  several 
simple serological tests for the prediction of fibrosis 
in chronic HCV infection: number of platelets, the 
APRI test, the Forns score, the Lok score and the 
FIB-4 score; as compared to LSM by TE and to the 
current “gold standard”: the LB.
Materials and Methods
Patients
The  study  was  retrospective  and  included  150 
cases  of  chronic  HCV  infection  admitted  to  the 
Department  of  Gastroenterology  and  Hepatology, 
Timişoara during January-December 2008. In all of 
these patients, in the same session, liver stiffness (LS) 
was evaluated by means of TE (FibroScan®); LB 
was performed in order to assess the stage of fibrosis; 
and the biological samples needed to calculate the 
scores were collected. Also, all of the patients were 
evaluated by abdominal ultrasound to exclude those 
with ascites. Patients with other causes of chronic 
hepatitis  (Hepatitis  B  virus  [HBV]  infection, 
chronic alcohol abuse, cholestatic chronic hepatitis, 
nonalcoholic  steatohepatitis,  autoimmune  chronic 
hepatitis, haemochromatosis, Wilson’s disease) were 
excluded from our study, based on negative hepatitis 
B  surface  antigen  (HBsAg),  negative  history  of 
alcohol abuse, no cholestasis on biological tests, no 
or mild steatosis on abdominal ultrasound and LB, 
normal  iron  load,  normal  ceruloplasmin,  negative 
markers of autoimmune hepatitis or primary biliary 
cirrhosis,  and  no  signs  of  biliary  obstruction  on 
abdominal ultrasound. 
Informed consent was obtained from each patient 
included in the study and the study protocol was 
approved by the local ethical committee.
LSM by means of TE
TE was performed on all of the 150 patients with 
a FibroScan® device (EchoSens® - Paris, France) by 
3 experienced physicians. In each patient, 10 valid 
measurements were taken, after which a median value 
of LS was calculated, measured in kiloPascals (kPa). 
Only patients in which LSMs had a success rate of 
at least 60%, with an interquartile range (IQR) of 
<30%, were included in our study. The success rate 
was calculated as the ratio of the number of successful 
acquisitions to the total number of acquisitions. IQR 
is the difference between the 75th percentile and the 
25th percentile, essentially the range of the middle 
50% of the data.
Liver biopsy 
Echoassisted LB was performed on all 150 patients 
using Menghini-type modified needles, 1.4 and 1.6 
mm in diameter. Only LB fragments of at least 2 
cm, including at least 8 portal tracts were considered 
adequate  for  pathological  interpretation  and  were 
included  in  the  study.  All  the  LBs  were  assessed 
according to the Metavir score by a senior pathologist. 
Fibrosis was staged on a 0–4 scale: F0 - no fibrosis; F1 
- portal fibrosis without septa; F2 - portal fibrosis and 
a few septa extending into lobules; F3 - numerous 
septa extending to adjacent portal tracts or terminal 
hepatic venules and F4 – cirrhosis.
Biological tests
Biological  tests  were  performed  on  blood 
collected by venous puncture in a single laboratory 
at  the  County  Emergency  Hospital  in Timişoara. 
All  biological  tests  are  routinely  evaluated  in  this 
laboratory:  AST  -  normal  values  5-34  U/l;  ALT: 
normal values 10-35 U/l; GGTP: normal values 12-
64 U/l; platelets: normal values 150,000-450,000/
mm3;  INR:  normal  values  0.88-1.10;  cholesterol: 
normal values <200 mg%.
Serological tests for assessing fibrosis
We evaluated the following serological tests for 
the assessment of fibrosis: 
The platelet count a) 
The  APRI  score  (AST/Platelet  ratio  index)  is  b) 
calculated according to the formula: 
APRI = [(AST/ULN) x 100]/platelet count 109/L
where ULN = the upper limit of normal.
The  Forns  score,  calculated  according  to  the  c) 
formula:
Forns score = 7.811 - 3.131 x ln [platelet count 
(109/L)] +
+  0.781  x  ln[(GGTP  (IU/L)]  +  3.467  x  ln 
[age(years)] – 0.014 [cholesterol (mg/dL)]
The Lok score, calculated according to the formula:  d) 
Log odds = - 5.56 – 0.0089 x platelet count (103/
mm3) + 1.26 x (AST/ALT) + 5.27 x INR
Lok = [exp (logodds)]/[1 + exp (logodds)] Hepatitis Monthly, Spring 2010; 10(2): 88-94
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The  FIB-4  score,  calculated  according  to  the  e) 
formula: 
FIB-4 = [age (years) x AST (IU/L)]/[platelet count 
(109/L) x ALT (IU/L)1/2]
Statistical analysis 
Data obtained from the patients were collected in a 
Microsoft Excel file. For a statistical study of quantitative 
variables,  the  mean  and  standard  deviations  were 
calculated. The diagnostic performances of LSMs and 
of the serologic tests were assessed by using the area 
under the receiver operating curve (AUROC), the most 
widely used indicator of accuracy (when the AUROC 
value is approaching 1, the accuracy is high). ROC 
curves were thus built for the detection of significant 
fibrosis (F ≥ 2 Metavir) and cirrhosis (F = 4 Metavir). 
Optimal cut-off values were chosen to maximize the 
sum of sensitivity (Se) and specificity (Sp). Positive 
predictive  values  (PPV),  negative  predictive  values 
(NPV), positive likelihood ratios (+LR) and negative 
likelihood ratios (-LR) were also assessed. We calculated 
95% confidence intervals (CI) of the AUROC curves 
to compare their predictive values. We also evaluated 
the correlation between the non-invasive tests and the 
histological severity of fibrosis. Statistical analysis was 
performed  using  Microsoft  Excel,  GraphPad  Prism 
and MedCalc programs. 
Results
Patients
The  study  group  included  150  patients:  102 
women (68%) and 48 men (32%). The mean age of 
the patients was 50.4±10.3 years, ranging from 18 
to 65 years. In the studied group, 1.3% (2 patients) 
had no fibrosis (F0); 9.3% (14 patients) had stage 1 
fibrosis (F1); 46% (69 patients) had stage 2 fibrosis 
(F2); 33.3% (50 patients) had stage 3 fibrosis (F3); 
and 10% (15 patients) had cirrhosis (F4), according 
to the Metavir score (Fig. 1). 
LS measurements were obtained for only 144 out 
of the 150 patients (96%).
Correlation with the histological severity of fibrosis
All  of  the  non-invasive  tests  were  statistically 
significantly correlated to the severity of fibrosis, either 
directly (APRI score, Forns, Lok and FIB-4 scores); 
or inversely (platelet count), as seen in Table 1. The 
strongest correlation was found for the APRI score 
(r = 0.570) and LSM ( r= 0.5694). 
Prediction of significant fibrosis (F ≥ 2 Metavir) 
The  results  of  the  statistical  analysis  of  the 
predictive  value  of  the  non-invasive  tests  for  the 
presence  of  significant  fibrosis  are  summarized  in 
Table 2. All the tests had very good positive predictive 
values (PPV) (95-100%), good specificity (Sp), but 
their sensitivity (Se) and negative predictive value 
(NPV) were low. 
We compared the AUROC curves of the 6 non-
invasive tests, built for the prediction of significant 
fibrosis (F ≥ 2 Metavir), by using the 95% CI and 
the  standard  error  of  the  mean  (SE),  and  found 
that although the LSM, done by means of TE and 
the APRI score, seem to have a somewhat better 
predictive  value  (larger  AUROC);  the  differences 
are  not  statistically  significant,  both  between  the 
two mentioned tests, and in the other tests evaluated 
(P > 0.05) (Fig. 2).
Prediction of cirrhosis (F = 4 Metavir)
The results of statistical analysis on the predictive 
value of the non-invasive tests for the presence of 
cirrhosis are summarized in Table 3. All of the tests 
have very good NPV (>97%), also good Se (>80%) 
and Sp, thus allowing the exclusion of cirrhosis.
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Figure 1. Severity of fibrosis in the studied group.
Table 1. Correlation between the evaluated tests and the severity of fibrosis.
Test Range Correlation score r 95% CI P-value
Platelet count 89,000-399,000/mm3 -0.4842 -0.6012 to -0.3470 <0.0001
APRI score 0.16 - 4.3 0.570 0.4483-0.6726 <0.0001
Forns score 0.74 - 10.04 0.540 0.4118-0.6473 <0.0001
Lok score 0.02 - 0.6 0.4843 0.3466-0.6016 <0.0001
FIB-4 score 0.22 - 6.63 0.4171 0.2707-0.5446 <0.0001
LSM 3.1 - 26.3kPa 0.5694 0.4436-0.6732 <0.0001Hepatitis Monthly, Spring 2010; 10(2): 88-94
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We compared the AUROC curves of the 6 non-
invasive tests, built for the prediction of cirrhosis 
(F  =  4  Metavir),  by  using  the  95%  CI  and  the 
SE, and found out that LSM by TE is the best 
method for predicting cirrhosis, significantly better 
than platelet count (P = 0.022) and than FIB-4 
(P  =  0.042);  otherwise  the  differences  were  not 
statistically significant (P > 0.05) (Fig. 3).
Discussion 
Non-invasive  tests  for  the  assessment  of  the 
severity  of  hepatic  fibrosis  are  gaining  ever  more 
ground among hepatologists, who are now put in 
the difficult position of choosing which one to use, 
taking  into  account  that,  at  this  time  more  than 
20 biochemical tests are available, not to mention 
elastographic methods (14).
All of these non-invasive tests have good PPV 
for the diagnosis of minimal or absent fibrosis and 
severe fibrosis, respectively (15-18); but their practical 
usefulness is limited by such factors as the need to 
standardize methods of determining the parameters 
taken into account for the test in question (FibroTest), 
the  high  cost  of  the  device  (FibroScan),  and  the 
possibility of false positive and false negative results. 
Platelet  count.  Starting  from  the  fact  that 
thrombocytopenia is a recognized complication of 
liver cirrhosis, usually secondary to hypersplenism, 
an attempt was made to establish its predictive value 
for the severity of fibrosis in chronic HCV infection. 
Two large studies published in 2005 showed that a 
cut-off of 150,000/mm3 in the platelet count had a 
PPV of 90% for the presence of cirrhosis. Also, a 
platelet count higher than 150,000/mm3 had a NPV 
of 90% for cirrhosis (19, 20).
 In our study we found that the platelet count, 
Table 2. Predictive value of the non-invasive tests for the presence of significant fibrosis (F ≥ 2 Metavir).
Test  Cut-off AUROC SE 95% CI P-value
Se
(%)
Sp
(%)
PPV
(%)
NPV
(%)
+
LR
-
LR
Platelet count (/mm3) 176,000 0.732 0.0746 0.650-0.798 <0.0001 37.3 100 100 16 - 0.63
APRI 0.52 0.766 0.0539 0.688-0.833 <0.0001 70 81 97 24.5 2.81 0.40
Forns 4.57 0.748 0.0566 0.668-0.816 <0.0001 71.6 68.5 95 24 2.29 0.41
Lok 0.17 0.701 0.0627 0.619-0.774 0.0009 57.5 81.2 96.2 18.6 3.06 0.52
FIB-4 2.1365 0.686 0.0644 0.603-0.761 0.0085 35.8 100 100 15.7 - 0.64
LSM (kPa) 6.8 0.773 0.0553 0.678-0.824 <0.0001 60.5 73.4 95 17.7 3.53 0.64
Figure  2.  AUROC  curves  for  the  prediction  of 
significant fibrosis (F ≥ 2 Metavir) of the evaluated 
non-invasive tests.
Figure 3. AUROC curves for the prediction of cirrhosis 
(F = 4 Metavir) of the evaluated non-invasive tests.
Table 3. Predictive value of the non-invasive tests for the presence of cirrhosis (F = 4 Metavir).
Test  Cut-off AUROC SE 95% CI P-value
Se
(%)
Sp
(%)
PPV 
(%)
NPV 
(%)
+
LR
-
LR
Platelets (/mm3) 155,000  0.899 0.0301 0.838-0.943 <0.0001 86.7 83.7 37.1 98.3 5.32 0.16
APRI 1.38 0.909 0.0519 0.850-0.951 <0.0001 93.3 83 37.8 99 5.48 0.08
Forns 5.93 0.911 0.0514 0.852-0.952 <0.0001 100 74 30 100 3.86 0
Lok 0.26 0.873 0.0596 0.808-0.923 <0.0001 86.7 82.2 35.1 98.2 4.87 0.16
FIB-4 2.3122 0.842 0.0649 0.772-0.898 <0.0001 80 77.8 28.6 97.2 3.6 0.26
LSM (kPa) 13.3  0.979 0.0262 0.850-0.951 <0.0001 93.3 96.1 73.7 99.2 24.08 0.07Hepatitis Monthly, Spring 2010; 10(2): 88-94
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indirectly,  was  statistically  significantly  correlated 
with the severity of fibrosis: r = - 0.4842 (95%CI: 
-0.6012 to -0.3470), P < 0.0001. Also, a platelet 
count  smaller  than  the  cut-off  value  of  176.000/
mm3 proved to be a predictor with a high Sp-100% 
of significant fibrosis (F≥2 Metavir) but with a low 
Se (37.3%), with 100% PPV, but with a low NPV-
16%. Using this cut-off value, 68% (102/150) of the 
patients were correctly classified as either having, or 
not having, significant fibrosis.
Regarding cirrhosis, a platelet count higher than 
155.000/mm3 proved to be a good predictor for the 
exclusion  of  cirrhosis,  with  83.7%  Sp,  86.7%  Se 
and 98.3% NPV, also with 5.32 +LR. For this cut-
off, 91% (137/150) of the patients were correctly 
classified as having or not having cirrhosis. 
The APRI score is not an expensive test, and thus 
within reach of any clinician. Various studies report 
quite  different  performance  scores  for  the  staging 
of fibrosis in HCV chronic hepatitis: 41-91% Se, 
47-95% Sp and 60-82.7% accuracy for predicting 
significant fibrosis (F ≥ 2 Metavir); 38.4-65.8% Se, 
86.7-93% Sp and 60-88% diagnostic accuracy for 
predicting cirrhosis (21-23). 
A meta-analysis (24) from 2007 proved that for 
a cut-off value of 0.5, the APRI score had 81% Se 
and 50% Sp for predicting significant fibrosis (F ≥ 2 
Metavir) and that for a cut-off value of 1, the Se and 
Sp for predicting cirrhosis were 76% and 71%. 
In our study, for a cut-off value of 0.52, the APRI 
score had 70% Se and 81% Sp for predicting significant 
fibrosis (F ≥ 2 Metavir), with 97% PPV and 24.5% 
NPV and 2.81 +LR. For a cut-off value of 1.38, the 
APRI score had 93.3% Se, 83% Sp and 5.48 +LR for 
the diagnosis of cirrhosis. For the cut-off value of 0.5 
proposed  by  Shaheen  meta-analysis  (24),  the  APRI 
was slightly more sensitive (73% vs. 70%), but not 
as specific (75% vs. 80%) for predicting significant 
fibrosis (F ≥ 2 Metavir). For cirrhosis prediction, at 
the cut-off value of 1 (24) Se remained at 93.3%, but 
the Sp decreased significantly to 69% (vs. 83%).
For a cut-off value of 0.52, 71% (107/150) of 
the patients were correctly classified as having or not 
having significant fibrosis, and for a cut-off value 
of 1.38, 82% (123/150) of patients were correctly 
classified as having or not having cirrhosis. For a cut-
off value of 1, as recommended by Shaheen, 70.6% 
(106/150) were correctly classified. 
The  Forns  score  is  a  simple  score  that  takes 
into  account  the  patient’s  age,  GGTP  and  serum 
cholesterol  levels  and  the  platelet  count.  The 
prediction accuracy for significant fibrosis in chronic 
HCV infection was reported to be between 50 and 
85% (23, 25). The value of this test is lower than of 
the FibroTest in the diagnosis of significant fibrosis 
(26,  27).  Also,  the  Forns  score  does  not  provide 
information on cirrhosis, leaving almost half of the 
cases unclassified (28).
In  our  study,  for  a  cut-off  value  of  4.57,  the 
Forns  score  had  71.6%  Se  and  68.5%  Sp  in 
discriminating significant fibrosis (F ≥ 2 Metavir), 
with  95%  PPV,  24%  NPV  and  2.29  +LR.  
A  Forns  score  higher  than  4.2  (low  cut-off  value 
recommended  by  the  authors  of  the  score)  had 
76% Se, 56% Sp, 93.6% PPV and 22 % NPV for 
predicting  significant  fibrosis,  meaning  that  the 
method is able to identify patients with significant 
fibrosis, but is not sensitive enough. For a cut-off 
value of 4.57, 71% (107/150) of the patients were 
correctly classified as having or not having significant 
fibrosis. 
The Lok score was proposed by the group led by 
Ann Lok during the Halt-C trial (20). According to 
the authors, for a cut-off value smaller than 0.2 to 
exclude cirrhosis, only 7.8% of patients had been 
wrongly  classified  (98%  Se,  53%  Sp,  27%  PPV 
and 99% NPV), and for values higher than 0.5 to 
confirm cirrhosis, only 14.8% of patients had been 
wrongly classified (40% Se, 99% Sp, 84% PPV and 
90% NPV).
In our study, for a cut-off value of 0.26 (which 
maximizes the sum of Se and Sp), the Lok score had 
86.7% Se and 82.2% Sp for cirrhosis discrimination 
(F = 4 Metavir), with 35.1% PPV, 98.2% NPV and 
4.87 +LR. At values lower than a cut-off of 0.2, the 
Lok score accurately excluded cirrhosis (99% NPV, 
93% Se, and 66% Sp). For values greater than a cut-
off of 0.5, Lok score accurately predicted cirrhosis 
(91.7% PPV, 98.5% Sp, 60% NPV and 20% Se). 
For  a  cut-off  value  of  0.5,  91.3%  (137/150)  of 
patients  were  correctly  classified  as  having  or  not 
having cirrhosis and for a cut-off value of 0.2, 69.3% 
(104/150) of patients were correctly classified. 
The  FIB-4  score  was  originally  developed  for 
human  immunodeficiency  virus  (HIV)-HCV 
coinfection,  but  was  confirmed  also  for  HCV 
infection, with performances similar to the FibroTest 
(29, 30) for the diagnosis of severe fibrosis (F3 and 
F4), with AUROC 0.85 (95%CI: 0.82-0.89). For 
values lower than a cut-off of 1.45, FIB-4 excluded 
severe fibrosis with a good NPV (94.7%), with 74% 
Se and 80% Sp. For values higher than a cut-off of 
3.25, FIB-4 confirmed severe fibrosis with 82% PPV, 
37.6%  Se  and  98%  Sp.  For  predicting  cirrhosis, 
FIB-4 had an AUROC of 0.91.
In our study, for a cut-off value of 2.1365, the FIB-4 
score had 35.8% Se and 100% Sp in discriminating 
significant fibrosis (F ≥ 2 Metavir), with 100% PPV 
and 15.7% NPV, 42% of the patients (64/150) being 
correctly classified as having or not having significant Hepatitis Monthly, Spring 2010; 10(2): 88-94
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fibrosis.  Also,  for  a  cut-off  of  2.3122,  FIB-4  had 
80% Se and 77.8% Sp in cirrhosis discrimination, 
with 28.6% PPV, 97.2% NPV and 3.6 +LR, 98% 
(147/150) of the patients being correctly classified as 
having or not having liver cirrhosis. 
LSM by means of  TE is a method which has 
been proved useful for predicting significant fibrosis 
(cut-off  values  7.1-8.7kPa)  and  cirrhosis  (cut-off 
values 12.5-14.5kPa) (17, 31). A recent meta-analysis 
(32) has confirmed the excellent performance of TE 
for the diagnosis of cirrhosis: mean AUROC - 0.94 
(95% CI: 0.93-0.95). As to its predictive value for 
significant fibrosis (F≥2 Metavir), the mean AUROC 
was 0.85 (95% CI: 0.81-0.87), the suggested cut-off 
being 7.65 kPa.
In our study, for a cut-off value of 6.8 kPa, LS had 
60.5% Se, 73.4% Sp for discriminating significant 
fibrosis (F ≥ 2 Metavir), with 95% PPV, 17.7% NPV 
and 3.53 +LR, 66% (95/144) of the patients being 
correctly classified as having or not having significant 
fibrosis. For a cut-off value of 13.3 kPa, LS had 93.3% 
Se,  96.1%  Sp  for  the  diagnosis  of  cirrhosis,  with 
73.7% PPV, 99.2% NPV and 24.08 +LR, 96.5% 
(137/144) of the patients being correctly classified as 
having or not having cirrhosis. 
When  we  compared  the  AUROC  curves  built 
to assess the predictive value for significant fibrosis 
of  the  evaluated  non-invasive  tests,  we  found  no 
statistically  significant  differences,  even  if  LSM 
(AUROC  0.773)  and  the  APRI  score  (AUROC 
0.766) seem to be better (with a larger AUROC) (P 
> 0.05). The weakest predictive values were found for 
the Lok score (AUROC 0.701) and the FIB-4 score 
(AUROC 0.686), both scores initially developed for 
the  prediction  of  cirrhosis  (Lok),  or  severe  fibrosis 
(FIB-4). Considering LR according to Jaeschke et al. 
(33), when values higher than the cut-off ones for APRI 
score, Forns score, Lok score and LSM were obtained, 
the probability of patients having significant fibrosis (F 
≥ 2) was significantly increased (+LR: 2.81, 2.29, 3.06 
and 3.53 respectively), while smaller values then the 
calculated cut-offs, for the all the investigated testes, 
had  poor  predictive  value  for  excluding  significant 
fibrosis (-LR ranging from 0.4 to 0.64). 
As for cirrhosis, all the tests had excellent predictive 
values, with AUROCs of 0.839-0.979. LSM was the 
best  method  for  predicting  cirrhosis,  significantly 
better  than  platelet  count  (P  =  0.022)  and  than 
FIB-4 (P = 0.042), otherwise the differences were not 
statistically significant (P > 0.05). In terms of LRs, 
LSM was the best test to predict or exclude cirrhosis 
(+LR 24.08 and –LR 0.07). All the tests had very 
good –LRs (ranging from 0 to 0.26), meaning that a 
negative test was very good for excluding cirrhosis.
One limitation of our study is the fact that it is a 
retrospective one; and another is the small number of 
cirrhotic patients. Also, several published studies stated 
the  influence  of  inflammation  (34,  35),  steatosis  (35) 
and ALT flares (36) on LSMs in patients with chronic 
HCV  infection.  These  factors  were  not  taken  into 
consideration in our study.
Conclusions
LSM by means of TE seems to be more sensitive 
than APRI, Forns, Lok and FIB-4 scores and platelet 
count  for  the  prediction  of  significant  fibrosis, 
but the differences are not statistically significant. 
APRI  score  and  Forns  scores  correctly  identified 
most (71%) of the patients as having or not having 
significant  fibrosis. LSM  was  the  best  method  for 
predicting cirrhosis, but all the evaluated tests had 
excellent predictive value (AUROCs 0.839-0.979).
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